TOP > 外国特許検索 > TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT

TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT

外国特許コード F170008935
整理番号 (AF42P001)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP062757
国際公開番号 WO 2016178374
国際出願日 平成28年4月22日(2016.4.22)
国際公開日 平成28年11月10日(2016.11.10)
優先権データ
  • 特願2015-093980 (2015.5.1) JP
発明の名称 (英語) TUMOR CELL MALIGNANT TRANSFORMATION SUPPRESSOR AND ANTI-TUMOR AGENT
発明の概要(英語) The present invention provides an anti-tumor agent and a suppressor for suppressing malignant transformation of tumor cells through means such as acquisition of metastasis capability and acquisition of apoptosis resistance. The present invention pertains to: a tumor cell malignant transformation suppressor that suppresses or inhibits acquisition of metastasis capability or acquisition of apoptosis resistance by tumor cells and of which the active ingredient is a substance that suppresses or inhibits the function of the Zic5 gene; a method for suppressing malignant transformation of tumor cells in an animal other than human, wherein acquisition of metastasis capability or acquisition of apoptosis resistance by tumor cells is suppressed or inhibited by suppressing or inhibiting the function of the Zic5 gene; an anti-tumor agent that is used for treating prostate cancer and of which the active ingredient is a substance that suppresses or inhibits the function of the Zic5 gene; and a tumor cell malignancy marker which is the expression level of the Zic5 gene.
従来技術、競合技術の概要(英語) BACKGROUND ART
Malignant melanoma is, in the melanocytes melanogenic cells with malignant tumor that is cancerous. Healing but with early detection, which causes remoteness in cases as low as 5 - year survival rate is about 10%, effective therapy has not been established (for example, see non-patent document 1 and 2.). In addition, greater than or equal to about 60-70% of the cases BRAFV600E gene also has been confirmed. BRAF downstream MEK (MAPK path MAPKKK) (MAPK path MAPKK) phosphorylate activated, further downstream by activated MEK ERK (MAPK path MAPK) is phosphorylated by activating, growth, survival, invasion, metastasis related to many proteins are activated (for example, see non-patent document 3.). BRAFV600E and strong constitutively BRAF mutation is activated, one cause of melanoma 1 and, at present, with respect to the selective inhibitors of mutant BRAF (PLX4032, vemurafenib) was used in clinical trials, have been confirmed by response rate is high. However, gene expression or splicing variant of BRAF, secreted from the stromal cells such as the expression of hepatocyte growth factor (HGF), by various mechanisms, BRAF inhibitor drug resistance to occur, the effect thereof is limited has been reported (for example, see non-patent document 4-6.).
Epithelial cancers that gains the ability to cause the transition as one of 1, epithelial mesenchymal transformation (Epithelial Mesenchymal Transition; EMT) has been known. Is EMT, epithelial-mesenchymal cell transformation of the cells to obtain phenomenon, resulting in EMT, epithelial cell adhesion molecule expression between E- cadherins is known as the amount of power. In addition, the EMT, Snail, Slug, Twist is controlled by a transcription factor such as the film has been made clear, these factors to control expression of cadherin E- or the like, are known to cause EMT (for example, see non-patent document 7.).
In melanoma, metastasis cases and many EMT is changing expression of the associated gene, one of the causes of transition enhancement EMT program is suggested (for example, see non-patent document 8.). Also, melanoma with mutations in BRAF, Zeb1 by of the constitutively activated BRAF, induced expression of transcription factors such as Twist 1, suppression of expression of the cadherin E- by a factor of these occurs, caused exacerbation of the melanoma cell-like phenomenon has been observed that the EMT (for example, see non-patent document 9.). E - The expression level of cadherin in many melanoma has a reduced, decreased expression of cadherin E- are significantly elevated in cases that the recurrence rate is reported (for example, see non-patent document 10.). These findings suggest that, reduced expression of cadherin E- exacerbation of melanoma and has been suggested to be associated with.
On the other hand, as well as cancer EMT, a critical phenomenon at the time of occurrence of the initial embryos and, the original intestinal intussusception and are involved in the differentiation of neuroepithelial cells. Neuroepithelial cells, part of the dorsal neural tube cause EMT, departing from the epithelial tissue and gains the ability to move, the peripheral nervous system, glial cells, satellite cells, melanocytes, fibroblasts ivory, craniofacial and differentiate into cartilage and the like. In neuroepithelial cells EMT, Snail, Slug, Twist E- by transcription factors such as is induced on the reduced expression of cadherin (for example, see non-patent document 7 and 11.).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • FUKAMI Kiyoko
  • SATOW Reiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) CREST Creation of Innovative Technology for Medical Applications Based on the Global Analyses and Regulation of Disease-Related Metabolites AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close